Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKesson
Colorcon
Boehringer Ingelheim
Merck

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR CEFAZOLIN AND DEXTROSE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cefazolin And Dextrose

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00108433 ↗ Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections Terminated Pfizer Phase 3 2005-09-01 This study will treat hemodialysis patients who have a central catheter that is thought to be infected with a specific bacteria (Gram positive bacteria).
NCT00130754 ↗ Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation Completed Hadassah Medical Organization Phase 3 2005-02-01 Allogeneic stem cell transplantation is the treatment of choice for a growing number of malignant and non-malignant indications. Until recently, myeloablative in conjunction with immunosuppressive conditioning was considered mandatory for the elimination of malignant hematopoietic cells and to prevent graft rejection. The aim of allogeneic non-myeloablative stem cell transplantation (NST) is to induce host-to-graft tolerance with fast and durable engraftment of donor stem cells, by means of conditioning, which is well-tolerated by patients. The rationale behind the NST strategy is to induce optimal graft-versus-leukemia (GVL) effects for the elimination of all malignant cells by alloreactive immunocompetent cells from a matched donor as an alternative to standard high-dose myeloablative chemo radiotherapy. The NST protocol is therefore mainly based on immunosuppression and thus contains fludarabine, low dose busulfan and anti-T-lymphocyte globulin (ATG). Thymoglobuline is a polyclonal rabbit antiserum specific for human T cells used in organ transplantation for induction of tolerance and rejection prevention and treatment. It was also used in stem-cell transplantation (SCT) for the same purposes (e.g. for generation of tolerance and rejection preclusion) as well as a treatment for graft-versus-host disease (GVHD). Data from myeloablative protocols suggest that ATG before SCT significantly reduces the risk for grade III-IV acute GVHD. This does not translate to a reduction in transplant-related mortality (TRM) because of the increased risk for infections and thus survival is unchanged. Extensive chronic GVHD was also significantly shown to be reduced in patients receiving ATG in the myeloablative setting. However, the role of ATG in the NST protocol was never evaluated in a prospective randomized trial. In view of the preliminary data suggesting of an additive effect of ATG in these circumstances we, the investigators at Hadassah Medical Organization, evaluate the effect of ATG in NST by a prospective randomized trial.
NCT00323219 ↗ Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department Unknown status University of British Columbia Phase 3 2004-01-01 Patients often come to the emergency department with bacterial skin infections (known as "cellulitis"). Some patients with very severe infections are admitted to hospital for antibiotic treatment and some are sent home on oral antibiotics. Many patients have moderate infections and are treated as outpatients with daily intravenous antibiotics for 2-5 days. In this patient group it is unclear if treatment with oral antibiotics is as effective as intravenous antibiotics. The purpose of this study is to determine if treatment of moderate cellulitis with an intravenous antibiotic (cefazolin) for 3-5 days is as effective as treatment with an oral antibiotic (moxifloxacin). We hypothesize that the oral agent will be as effective as intravenous treatment for moderate cellulitis.
NCT00330278 ↗ Timing of Prophylactic Antibiotics for Cesarean Sections Completed Medical University of South Carolina N/A 2003-01-01 This is a randomized, double-blinded placebo controlled trial of cefazolin timing before cesarean section fo infection prophylaxis. Subjects are randomized to cefazolin either 30 minutes prior to skin incision or at time of cord-clamping. Primary outcome is infectious morbidity including wound infections and endometritis.
NCT00467948 ↗ Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients Completed Tehran University of Medical Sciences Phase 3 2004-06-01 Patients who need major head & neck surgery are at risk of post operative wound infection. In spite of role of antibiotics in prophylaxis of clean contaminated head and neck surgery has been well documented, controversy exists in the optimal antibiotic regimen
NCT00550290 ↗ Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy Completed Aultman Health Foundation Phase 4 2007-10-01 This randomized prospective study will specifically investigate the efficacy of a 24 hour post-operative course of broad-spectrum prophylactic antibiotics - namely Cefazolin - in preventing wound infection and wound breakdown following vulvectomy.
NCT00610987 ↗ Antibiotic Prophylaxis in Orthopaedic Traumatology Completed University of Missouri-Columbia N/A 2008-01-01 It has been established that providing antibiotic prophylaxis after closed fracture fixation with implants or prosthetic devices has beneficial effects. However, the optimal duration of antibiotic prophylaxis after orthopaedic trauma surgery is not well-defined. Most studies comparing single-dose prophylaxis with multiple-dose prophylaxis have not shown beneficial effects of additional doses. Our proposed study is intended to further define the appropriate duration of antibiotic (cefazolin) administration for surgical prophylaxis in the treatment of closed fractures. We will randomly assigned patients into two groups, hopefully differentiated only by the duration of antibiotic administration (single dose vs. 24 hours). We will follow these patients until fracture healing and determine if there is a difference in the incidence of infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cefazolin And Dextrose

Condition Name

Condition Name for Cefazolin And Dextrose
Intervention Trials
Surgical Site Infection 11
Infection 7
Obesity 7
Wound Infection 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cefazolin And Dextrose
Intervention Trials
Infections 36
Infection 29
Surgical Wound Infection 20
Communicable Diseases 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cefazolin And Dextrose

Trials by Country

Trials by Country for Cefazolin And Dextrose
Location Trials
United States 128
Canada 23
Brazil 10
Australia 10
New Zealand 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cefazolin And Dextrose
Location Trials
Texas 9
New York 9
California 9
Pennsylvania 8
North Carolina 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cefazolin And Dextrose

Clinical Trial Phase

Clinical Trial Phase for Cefazolin And Dextrose
Clinical Trial Phase Trials
Phase 4 50
Phase 3 22
Phase 2/Phase 3 5
[disabled in preview] 63
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cefazolin And Dextrose
Clinical Trial Phase Trials
Completed 66
Recruiting 25
Unknown status 22
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cefazolin And Dextrose

Sponsor Name

Sponsor Name for Cefazolin And Dextrose
Sponsor Trials
B. Braun Medical Inc. 4
Population Health Research Institute 4
University of Sao Paulo General Hospital 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cefazolin And Dextrose
Sponsor Trials
Other 202
Industry 20
NIH 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Baxter
McKesson
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.